Relatlimab for melanoma

[Kroll2013]

---

Members don't see this ad.

In what situation would you recommend relatlimab + nivolumab over ipilimumab + nivolumab in the treatment of metastatic melanoma?

 

[RickyScott]

I don’t even know what relatimab is and I treat a lot of melanoma.

 

[Gfunk6]

In what situation would you recommend relatlimab + nivolumab over ipilimumab + nivolumab in the treatment of metastatic melanoma?

When the Med Onc consult note says so

 

[evilbooyaa]

I don’t even know what relatimab is and I treat a lot of melanoma.

https://www.nejm.org/doi/full/10.1056/nejmoa2109970

I'm not really sure why the comparator arm is Nivo alone givn that Ipi/Nivo is the usual backbone for melanoma management....

Ah, yes, there it is - Bristol Myers Squibb is trying to get a new patentable IT out there as Ipilimumab comes off patent at the end of 2022 (source: List - 100 Biologics Patents Expiring Between 2022 to 2027 - GreyB)

Nivolumab? Expires 2023/2024. So expect relatlimab to be combined with their next generation PD-1 (or other target IT drug) sometime in the next 1-2 years.

Perhaps a small molecule inhibitor working on that axis - BMS-1001 or BMS-1166: Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells

 

[Palex80]

I'm not really sure why the comparator arm is Nivo alone givn that Ipi/Nivo is the usual backbone for melanoma management....

Cause that trial outcome may have been negative. 🙂

Ah, yes, there it is - Bristol Myers Squibb is trying to get a new patentable IT out there as Ipilimumab comes off patent at the end of 2022 (source: List - 100 Biologics Patents Expiring Between 2022 to 2027 - GreyB)

Of course!